| Name | 4EGI-1 |
| Description | 4EGI-1, a competitive eIF4E/eIF4 g interaction inhibitor, binds to eIF4E(KD=25 μM). |
| Cell Research | Cell viability is measured by treatment of Jurkat cells with compound for 24 h and by determination of intracellular ATP using the CellTiterGlo assay. For measurement of apoptotic DNA fragmentation, cells are treated for 24 h with 60 μM EGI-1 or 6.65 μM camptothecin in the presence or absence of 100 mM zVAD-FMK, a broad-spectrum caspase inhibitor. After fixation and staining with PI, cellular DNA content is determined by FACS analysis in a FACS Calibur machine. Nuclear morphology after 24 h EG1-1 treatment is visualized by staining of cells with Hoechst dye and ?uorescence microscopy. For the A549 lung cancer cells, cell growth in the presence of 4EGI-1 is determined using the SRB staining method.(Only for Reference) |
| In vivo | In Jurkat cells, 4EGI-1 promotes apoptosis. It effectively inhibits cell growth in A549 lung cancer cells (IC50=6 μM). In human lung cancer cells, 4EGI-1 enhances TRAIL-induced apoptosis by inducing DR5 and downregulating c-FLIP, thereby inhibiting cap-dependent protein translation. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45.1 mg/mL (100 mM)
|
| Keywords | 4EGI1 | Autophagy | 4EGI-1 | inhibit | Eukaryotic Initiation Factor (eIF) | Inhibitor | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Tributyrin | Curcumin | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Apoptosis Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
